Crosstalk between Pten and Ras signaling pathways in tumor development

Cell Cycle

Volumn 4, Issue 9, 2005, Pages 1185-1188

  To, Minh D ^a   Perez Losada, Jesus ^a   Mao, Jian Hua ^a   Balmain, Allan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AKT; Hras; MAPK; Pten; Skin carcinoma; Skin papilloma

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN;

BIOCHEMISTRY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL COMPARTMENTALIZATION; DISEASE COURSE; GENE ACTIVATION; GENE LOSS; GENE MUTATION; HETEROZYGOSITY; HUMAN; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE H RAS; PAPILLOMA; PROTEIN DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STEM CELL;

EID: 25444526166     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.9.2039     Document Type: Review

References (43)

1. Maehama T, Dixon JE. The tumor suppressor PTEN/MMAC1,dephosphorylates the lipid second messenger phosphatidylinositol 3,4,5-triphosphate. J Biol Chem 1998; 273:13375-8.
2. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997; 94:9052-7.
3. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
4. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333-4.
5. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-7.
6. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96:1563-8.
7. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19:348-55.
8. Suzuki A, Itami S, Ohishi M, Hamada K, Inoue T, Komazawa N, Senoo H, Sasaki T, Takeda J, Manabe M, Mak TW, Nakano T. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 2003; 63:674-81.
9. Kubo Y, Urano Y, Hida Y, Arase S. Lack of somatic mutation in the PTEN gene in squamous cell carcinomas of human skin. J Dermatol Sci 1999; 19:199-201.
10. Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 1994; 54:4756-9.
11. Mao JH, To MD, Perez-Losada J, Wu D, Del Rosario R, Balmain A. Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev 2004; 18:1800-5.
12. Nuss DD, Aeling JL, Clemons DE, Weber WN. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol 1978; 114:743-6.
13. Camisa C, Bikowski JB, McDonald SG. Cowden's disease. Association with squamous cell carcinoma of the tongue and perianal basal cell carcinoma. Arch Dermatol 1984; 120:677-8.
14. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986; 322:78-80.
15. Balmain A, Ramsden M, Bowden GT, Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 1984; 307:658-60.
16. Mao JH, Wu D, Perez-Losada J, Nagase H, Del Rosario R, Balmain A. Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene 2003; 22:8379-85.
17. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000; 60:1800-4.
18. Ikeda T, Yoshinaga K, Suzuki A, Sakurada A, Ohmori H, Horii A. Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol Rep 2000; 7:567-70.
19. Navarro P, Valverde AM, Benito M, Lorenzo M. Activated Ha-ras induces apoptosis by association with phosphorylated Bcl-2 in a mitogen-activated protein kinase-in dependent manner. J Biol Chem 1999; 274:18857-63.
20. Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M, Fujita H, Yoshida M, Chen W, Asai A, Himeno M, Yokoyama S, Kuchino Y. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene 1999; 18:2281-90.
21. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 1990; 87:538-42.
22. Vassar R, Hutton ME, Fuchs E. Transgenic overepxression of transforming growth factor alpha bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis. Mol Cell Biol 1992; 12:4643-53.
23. Wang XJ, Greenhalgh DA, Eckhardt JN, Rothnagel JA, Roop DR. Epidermal expression of transforming growth factor-alpha in transgenic mice: Induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression. Mol Carcinog 1994; 10:15-22.
24. Ise K, Nakamura K, Nakao K, Shimizu S, Harada H, Ichise T, Miyoshi J, Gondo Y, Ishikawa T, Aiba A, Katsuki M. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 2000; 19:2951-6.
25. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks F, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hopper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Skipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417:906-7.
26. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001; 20:7812-6.
27. Megosh L, Halpern M, Farkash E, O'Brien TG. Analysis of ras gene mutational spectra in epidermal papillomas from K6/ODC transgenic mice. Mol Carcinog 1998; 22:145-9.
28. Rehman I, Lowry DT, Adams C, Abdel-Fattah R, Holly A, Yuspa SH, Hennings H. Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated by N-methyl-N′-nitro-N-nitrosoguanidine and promoted by mezerein. Mol Carcinog 2000; 27:298-307.
29. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
30. Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV, Martinez J, Larcher F, Slaga TJ, Gutkind JS, Jorcano JL, Paramio JM. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002; 21:53-64.
31. Zimmerman S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 280:1741-4.
32. Reusck HP, Zimmerman S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 276:33630-7.
33. Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, Sasaki T, Mak TW, Nakano T. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197:657-67.
34. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, Yoshida R, Wakeham A, Higuchi T, Fukumoto M, Tsubata T, Ohashi PS, Koyasu S, Penninger JM, Nakano T, Mak TW. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14:523-34.
35. Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC. The distinct contributions of murine T cell receptor (TCR) gammadelta+ and TCR alphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198:747-55.
36. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in Pten and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32:355-7.
37. Brown K, Strathdee D, Bryson S, Lambie W, Balmain A. The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr Biol 1998; 8:516-24.
38. Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer 2003; 3:434-443.
39. Owens DM, Watt FM. Contribution of stem cells and differentiated cells to epidermal tumors. Nat Rev Cancer 2003; 3:444-51.
40. Hennings H, Shores R, Mitchell P, Spangler EF, Yuspa SH. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis 1985; 6:1607-10.
41. Groszer M, Erickson R, ScriptureAdams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H. Negative regulation of neural stem/progenitor cell proiferation by the Pten tumor suppressor gene in vivo. Science 2001; 294:2186-9.
42. Niemann C, Watt FM. Designer skin: Lineage commitment in postnatal epidermis. Trends Cell Biol 2002; 12:185-92.
43. Manning BD. Balancing Akt and S6K: Implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167:399-403.